TB-500

Mechanism

TB-500 is a synthetic version of a naturally occurring peptide called Thymosin Beta-4 that plays a key role in tissue repair. It promotes healing by stimulating new blood vessel formation, reducing inflammation, and encouraging cell migration to injured areas. It is commonly used for muscle tears, tendon injuries, and general recovery support.

Effects

**Musculoskeletal System (Tier 1 — Human + Extensive Animal):** TB-500 promotes healing of tendons, ligaments, muscles, and connective tissue by upregulating actin polymerization and cell migration. It recruits progenitor cells and satellite cells to injury sites, accelerating structural repair. Equine clinical trials (legally used in veterinary medicine) demonstrate faster recovery from suspensory ligament injuries and tendon tears. Human practitioner data (off-label) consistently reports accelerated recovery from rotator cuff injuries, Achilles tendinopathy, hamstring tears, and chronic joint issues. **Cardiovascular System (Tier 2 — Animal):** Thymosin Beta-4 (the parent molecule) shows cardioprotective effects post-myocardial infarction in animal models — reduces infarct size, promotes cardiac progenitor cell activation, and improves ejection fraction. TB-500 appears to retain these properties. Promotes angiogenesis in ischemic tissue. **Integumentary System (Tier 2 — Animal + In Vitro):** Accelerates wound healing by promoting keratinocyte and fibroblast migration. Reduces scar tissue formation through modulation of collagen deposition and cross-linking. Hair follicle stem cell activation observed in animal models — TB-500-treated mice showed new hair growth. **Immune & Anti-Inflammatory (Tier 2 — Animal + In Vitro):** Potent anti-inflammatory effects through suppression of NF-kB pathway and reduction of IL-1β, IL-6, and TNF-α. Promotes regulatory T-cell activity and resolvin production, shifting the immune response from inflammatory to reparative. Reduces fibrosis in liver, kidney, and lung injury models. **Nervous System (Tier 2 — Animal):** Promotes oligodendrocyte differentiation and myelination in CNS injury models. Neuroprotective in traumatic brain injury and spinal cord injury animal studies — reduces neural inflammation and promotes axonal regrowth. Crosses the blood-brain barrier. **Ocular (Tier 1 — Human Clinical):** Thymosin Beta-4 (as RGN-259) completed Phase III trials for dry eye disease, demonstrating significant improvement in corneal staining scores, the primary endpoint. This is the most advanced human clinical program for the TB-4 molecule.

Practitioner Guide

**LOADING PHASE DOSING (Standard Practitioner Protocol):** • Loading phase: 2.0–2.5 mg injected subcutaneously twice per week for 4–6 weeks. This front-loads tissue saturation and is considered essential by most practitioners for injury recovery. • Maintenance phase: 2.0–2.5 mg once per week for an additional 4–8 weeks after loading. Some practitioners extend maintenance to 12 weeks for chronic or severe injuries. • Total course: 8–14 weeks typical. Reassess at 8 weeks. If significant improvement, taper to biweekly. If minimal improvement, consider extending loading phase or adding complementary peptides. • Clinical pearl: Practitioners consistently report that skipping the loading phase produces markedly inferior results. The twice-weekly loading appears to be critical for establishing adequate tissue concentrations. **SYSTEMIC VS LOCAL INJECTION:** • Subcutaneous (systemic): Standard approach. Inject into abdominal fat fold, rotating sites. TB-500 distributes systemically due to its small size and actin-binding properties — it "finds" injury sites through preferential accumulation in damaged tissue with upregulated actin turnover. Most practitioners use systemic injection even for localized injuries and report excellent results. • Local/peri-lesional injection: Some practitioners inject 0.5–1.0 mg directly around the injury site (e.g., around an injured tendon or into a joint capsule) AND administer 1.5–2.0 mg subcutaneously. This dual approach may accelerate local healing while maintaining systemic benefits. Use 29–30G insulin syringes for peri-lesional injection. • Clinical pearl: TB-500 does NOT need to be injected directly into the injury to work. Systemic administration is the standard of care in peptide therapy. Local injection is optional and additive, not required. **THE BPC-157 + TB-500 STACK (The Classic Healing Combination):** • Rationale: BPC-157 and TB-500 work through complementary mechanisms. BPC-157 promotes angiogenesis (new blood vessel formation) via VEGF upregulation and modulates the nitric oxide system, while TB-500 promotes cell migration and actin-dependent tissue remodeling. Together, they provide vascular support + structural repair. • Standard stack protocol: BPC-157 250–500 mcg/day (subcutaneous) + TB-500 2.0–2.5 mg twice/week during loading. Many practitioners report this combination produces faster and more complete healing than either peptide alone. • Injection timing: Can be injected at the same time but in different sites (e.g., BPC-157 near the injury, TB-500 in the abdomen). Some practitioners mix them in the same syringe — this is pharmacologically acceptable as there is no known interaction, but some prefer separate injections for dose precision. • What practitioners observe: The BPC-157 + TB-500 stack is the single most commonly prescribed healing protocol in peptide therapy clinics. Practitioners consistently report: (1) Tendon/ligament injuries that were not progressing with physical therapy alone begin improving within 2–3 weeks. (2) Chronic tendinopathies (tennis elbow, plantar fasciitis, patellar tendinitis) that have been present for months show measurable improvement by 4–6 weeks. (3) Muscle tears and strains heal faster with less residual scar tissue. (4) Post-surgical recovery (ACL reconstruction, rotator cuff repair) appears accelerated when started 1–2 weeks post-op (after initial inflammatory phase). • When to add Thymosin Alpha-1: For injuries with a significant inflammatory or immune component (e.g., autoimmune-related joint issues, chronic infections around implants), adding Thymosin Alpha-1 (1.5 mg 2–3x/week) creates a triple immune-modulating + healing stack. **SPECIFIC INJURY PROTOCOLS (Practitioner Observations):** • Tendon injuries (Achilles, patellar, rotator cuff): BPC-157 500 mcg/day + TB-500 2.5 mg 2x/week for 6 weeks, then reassess. Pair with eccentric loading physical therapy starting week 2–3. Most practitioners report significant improvement by week 4–6. • Ligament sprains/tears (ACL, MCL, ankle): Same dosing as tendons. TB-500 may be particularly beneficial for ligaments given its actin-remodeling properties. Conservative management + peptides may reduce need for surgical intervention in partial tears. • Muscle strains/tears: BPC-157 250–500 mcg/day + TB-500 2.0 mg 2x/week for 4 weeks. Muscle injuries typically respond faster than tendons/ligaments. • Chronic joint pain/osteoarthritis: Lower doses over longer periods — BPC-157 250 mcg/day + TB-500 2.0 mg 1x/week for 12 weeks. Joint injections (intra-articular) of BPC-157 are practiced by some clinicians but require medical training. **RECONSTITUTION & STORAGE:** • Reconstitute with bacteriostatic water. TB-500 typically comes in 5 mg vials. Add 2 mL BAC water = 2.5 mg/mL concentration. • Refrigerate after reconstitution. Stable for 3–4 weeks refrigerated. • TB-500 is relatively heat-stable compared to other peptides but should not be left at room temperature once reconstituted. • Clinical pearl: TB-500 is very forgiving in terms of handling — it maintains biological activity even after moderate temperature fluctuations, unlike some more fragile peptides (e.g., GnRH analogs).

Dosing Protocols

Contraindications & Cautions

• hard stop — Active cancer
  TB-500 (thymosin beta-4 fragment) promotes cell migration, angiogenesis, and tissue remodeling. These mechanisms may facilitate tumor cell migration, metastasis, and tumor vascularization in patients with active malignancies.
  Action: Do not use in patients with any active cancer diagnosis. Patients with cancer history within the past 5 years should consult their oncologist before use.
• hard stop — Pregnancy
  No human safety data exists for TB-500 use during pregnancy. Cell migration and angiogenic properties pose theoretical risk to fetal development.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk or effects on nursing infants. Safety has not been established.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Cell migration and tissue remodeling properties pose unknown risks to developing physiology.
  Action: Do not provide peptide protocols to individuals under 18.

Stacks featuring this peptide

Research Summary

**Tier 1 (Human Clinical Evidence):** • Dry eye disease (RGN-259): Phase III trials of Thymosin Beta-4 eye drops demonstrated significant improvement in corneal staining scores vs placebo. This represents the most advanced human clinical data for any TB-4/TB-500 product. • Equine clinical trials (FDA-CVM regulated): Controlled studies in racehorses show accelerated tendon and ligament healing, reduced re-injury rates. Legally marketed in veterinary medicine in several countries. • Human practitioner data: Thousands of patients treated off-label in peptide therapy clinics. No formal Phase III human trials for musculoskeletal indications, but practitioner consensus is strong and consistent across clinics globally. **Tier 2 (Strong Preclinical + Mechanistic):** • Cardiac repair: Multiple animal studies (mouse, rat, pig) show TB-4/TB-500 reduces infarct size by 40–50%, promotes cardiac progenitor cell activation, and improves ejection fraction post-MI. Strong mechanistic basis through coronary vasculogenesis and cardiomyocyte survival signaling. • Neurological repair: Rodent TBI and spinal cord injury models show improved functional outcomes with TB-4 treatment — reduced inflammation, enhanced oligodendrocyte progenitor survival, and improved myelination. • Anti-fibrotic effects: Kidney, liver, and lung fibrosis models show TB-4 reduces collagen deposition and myofibroblast activation. Mechanism involves downregulation of TGF-β signaling. • Wound healing: Extensive animal data (rodent, porcine) demonstrates accelerated wound closure, improved tissue organization, and reduced scarring. **Tier 3 (Emerging / Theoretical):** • Stem cell mobilization: TB-4 may enhance endogenous stem cell mobilization and homing. Mechanism is plausible (actin dynamics are central to cell migration) but not fully characterized. • Anti-aging: Systemic tissue rejuvenation hypothesis based on broad regenerative effects. Speculative but mechanistically grounded. • Hair regrowth: Mouse studies show hair follicle stem cell activation. No human hair loss studies published.